BioInnovation Institute (BII) has awarded €7.8 million in additional funding to six companies developing technologies across healthcare, agriculture and sustainable energy.
Each company will receive €1.3 million to advance its technology and move closer to commercialisation. Having previously received €500,000 from BII, each has now secured a total of €1.8 million from the institute.
The six companies are:
- PanTarg, a spin-out from the University of Copenhagen and Rigshospitalet, is developing an antibody-based cancer treatment that combines two targeted approaches in a single therapy, with a focus on aggressive cancers including pancreatic cancer.
- 3Sonic, a spin-out from Rigshospitalet and the Technical University of Denmark (DTU), is developing an AI-powered 3D ultrasound technology that enables surgeons to assess cancer tissue in real time during surgery.
- Inia Biosciences is developing treatments for inflammatory diseases, initially targeting psoriasis. The company emerged from the innovation ecosystems in Boston and Oxford.
- Yngvi Bio, a University of Copenhagen spin-out, is developing biological pest control solutions designed to protect crops while reducing environmental and biodiversity impacts.
- Proxi Biotech, a spin-out from Statens Serum Institut (SSI), is developing vaccine-based immunotherapies for recurrent bacterial infections, initially targeting recurrent Clostridium difficile infections.
- Sagava, a DTU spin-out, is developing technology that converts waste into biogenic fuels and energy, with a focus on reducing emissions from the maritime sector.
Alongside the funding, the six companies will continue to have access to BII's innovation platform in Copenhagen, including laboratory facilities, a network of investors, advisors and strategic partners, and expertise in business development and commercialisation.
According to BII Chief Business Officer Trine Bartholdy, the companies have progressed from early research towards technologies with potential commercial applications.
We see significant potential in all six companies, and our role is to help them turn their technologies into sustainable businesses and products that can create value for patients, society and investors,
said Bartholdy.
The additional funding will support further technology development and commercialisation across the six companies, while helping them attract external capital and bring their products and solutions closer to market.
BII supports early-stage life science companies and research projects, with a focus on human health, biotechnology and planetary health.
Would you like to write the first comment?
Login to post comments